Charles River Laboratories International (NYSE:CRL) Sets New 12-Month Low – What’s Next?

Charles River Laboratories International, Inc. (NYSE:CRL)’s share price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $159.65 and last traded at $162.66, with a volume of 49248 shares. The stock had previously closed at $163.64.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on CRL shares. Redburn Atlantic assumed coverage on shares of Charles River Laboratories International in a report on Monday, October 14th. They issued a “sell” rating and a $151.00 target price on the stock. Bank of America cut their price target on Charles River Laboratories International from $220.00 to $210.00 and set a “neutral” rating on the stock in a research note on Friday, December 13th. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a report on Wednesday, January 22nd. StockNews.com cut shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research report on Thursday, November 7th. Finally, UBS Group restated a “neutral” rating and issued a $185.00 price objective (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Three analysts have rated the stock with a sell rating, thirteen have assigned a hold rating and one has assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $204.38.

Charles River Laboratories International Trading Down 1.2 %

The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The company has a market capitalization of $8.27 billion, a price-to-earnings ratio of 20.28, a P/E/G ratio of 5.94 and a beta of 1.38. The business’s 50 day moving average price is $185.87 and its two-hundred day moving average price is $196.49.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings results on Wednesday, November 6th. The medical research company reported $2.59 EPS for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. The firm had revenue of $1.01 billion for the quarter, compared to analyst estimates of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period last year, the firm posted $2.72 earnings per share. On average, equities analysts predict that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Richard F. Wallman sold 6,621 shares of the firm’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total transaction of $1,430,930.52. Following the completion of the transaction, the director now directly owns 12,386 shares in the company, valued at $2,676,862.32. This trade represents a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 1.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the company. North Growth Management Ltd. increased its position in shares of Charles River Laboratories International by 18.2% during the fourth quarter. North Growth Management Ltd. now owns 39,000 shares of the medical research company’s stock worth $7,168,000 after buying an additional 6,000 shares during the period. Sumitomo Mitsui DS Asset Management Company Ltd boosted its position in shares of Charles River Laboratories International by 2.3% during the 4th quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 5,951 shares of the medical research company’s stock worth $1,099,000 after purchasing an additional 133 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. increased its position in Charles River Laboratories International by 11.7% in the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 125,097 shares of the medical research company’s stock valued at $23,093,000 after buying an additional 13,102 shares in the last quarter. YANKCOM Partnership bought a new position in Charles River Laboratories International in the fourth quarter worth approximately $92,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Charles River Laboratories International by 46.4% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,301 shares of the medical research company’s stock valued at $987,000 after acquiring an additional 1,679 shares during the period. Institutional investors own 98.91% of the company’s stock.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).